查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
2020270

癌症診斷市場規模、佔有率、成長及全球產業分析：按類型、應用和地區分類，並預測至2026-2034年

Cancer Diagnostics Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 130 Pages | 商品交期: 請詢問到貨日

價格

癌症診斷市場成長要素

受癌症負擔日益加重、診斷技術不斷進步以及各國政府加大早期檢測力度等因素的推動，全球癌症診斷市場正經歷強勁成長。最新數據顯示，2025年該市場規模將達172.4億美元，預計2026年將達185.1億美元。到2034年，該市場預計將顯著成長至382.7億美元，2026年至2034年的複合年成長率（CAGR）為9.5%。

市場促進因素

乳癌、大腸癌和攝護腺癌等癌症發生率的不斷上升，是推動有效診斷方法需求成長的主要動力。例如，世界衛生組織（WHO）預測，到2050年，全球新增癌症病例將達到3,500萬例，比2022年的2,000萬例增加77%。早期準確診斷在降低死亡率方面發揮著至關重要的作用，這加速了包括免疫組織化學（IHC）、原位雜合反應（ISH）、分子診斷和液態生物檢體在內的先進診斷技術的應用。

各國政府和私人機構正加強意識提升。例如，美國的「社區大腸直腸癌防治計畫」（ACCION）、英國的「腸癌篩檢計畫」（BCSP）以及世界衛生組織的「全球根除子宮頸癌策略」等項目，旨在擴大篩檢和早期療育的範圍。這些舉措透過加速診斷技術的應用，推動了市場成長。

市場限制因素

儘管預計成長前景良好，但診斷程序的高成本和特定風險仍然是挑戰。例如，大腸鏡檢查是大腸直腸癌篩檢的黃金標準，但有出血、穿孔和器械相關感染疾病等風險。此外，PCR儀等先進診斷設備的價格在3000美元到30000美元之間，持續的維護成本限制了其普及，尤其是在新興市場。

市場機遇

亞太地區新興市場正迎來成長機遇，這得益於各國政府加大對醫療基礎設施的投資以及人們對遠端醫療的認知不斷提高。新冠疫情加速了遠距遠端醫療的普及，使得遠距癌症篩檢和諮詢成為可能。預計這一趨勢將持續下去，為那些缺乏充足醫療服務的人提供早期診斷和後續觀察的機會。

市場趨勢

市場參與者越來越關注產品發布、技術進步和夥伴關係。主要趨勢包括：

  • 2022 年 6 月：羅氏公司推出“BenchMark ULTRA PLUS”，旨在提高癌症的早期診斷率。
  • 2023 年 10 月：F. Hoffmann-La Roche、Ibex Medical Analytics 和 Amazon Web Services 合作，擴展其人工智慧驅動的前列腺癌和血液惡性腫瘤診斷工具。
  • 2024 年 4 月：美國生技公司 Novelna 開發了一种血液蛋白測試，可以高精度地檢測出 18 種早期癌症。
  • 2023 年 5 月：輝瑞和賽默飛世爾科技公司合作，在 30 多個國家/地區改善基於次世代定序(NGS) 的癌症診斷的可及性。
  • 2024 年 4 月：Bio-Rad Laboratories 推出了用於基於生物標記的診斷的 ddPLEX ESR1 突變檢測試劑盒。

細分分析

副產品：

  • 預計到 2026 年，檢測試劑盒和試劑將推動市場發展，佔 83.07% 的市場佔有率，這主要得益於診斷測試數量的增加和新產品的推出。
  • 受醫療保健支出不斷成長的推動，醫療設備市場預計將穩定成長。

就技術而言：

  • 免疫檢測因其在診斷乳癌、前列腺癌和其他癌症方面的有效性而佔市場領先地位。
  • 免疫組化技術有望成為成長最快的技術，這得益於其精準的診斷和治療預測能力。

按類型：

  • 組織切片檢查具有高精度和詳細的分子分析能力，預計到 2026 年將主導市場，佔 87.04% 的市場佔有率。
  • 液態生物檢體是成長最快的方法，因為它能快速提供結果（通常比組織切片檢查早 26.8 天）。

癌症類型：

  • 乳癌領域仍佔主導地位，反映出全球較高的發生率。
  • 年輕人吸菸率的上升正在推動肺癌市場快速擴張。

按最終用戶分類：

  • 由於臨床檢查室進行的檢測數量龐大且擁有先進的設備，因此它們在市場上佔主導地位。
  • 醫院和診所也不斷擴張，在同一機構內提供診斷和治療服務。

區域展望

  • 預計到 2025 年，北美將以 36.81% 的市佔率（63.5 億美元）引領市場，並在 2026 年達到 69 億美元，這主要得益於 Thermo Fisher Scientific、Abbott、Illumina 和 GE Healthcare 等公司的推動。
  • 預計到 2025 年，歐洲的全球經濟規模將達到 52.8 億美元，到 2026 年將達到 56.3 億美元，這得益於「10 萬基因組計劃」等夥伴關係項目和基因組計劃的支持。
  • 受中國、日本和印度等國家癌症負擔日益加重的推動，亞太地區預計到 2025 年將成長至 37.8 億美元，到 2026 年將達到 40.7 億美元。
  • 拉丁美洲、中東和非洲是規模雖小但正在成長的市場，預計到 2025 年，市場規模將分別達到 11.3 億美元和 6.9 億美元。

目錄

第1章：引言

第2章摘要整理

第3章 市場動態

  • 市場促進因素
  • 市場限制因素
  • 市場機遇

第4章：主要考慮因素

  • 2025年主要癌症的盛行率（按國家/地區分類）
  • 主要企業推出新產品
  • 近期產業趨勢－併購
  • 主要國家醫療保健成本概覽
  • 技術進步、診斷設備和試劑盒
  • 新冠疫情對癌症診斷市場的影響

第5章：2021-2034年全球癌症診斷市場分析、洞察與預測

  • 市場分析、洞察與預測：按產品分類。
    • 裝置
    • 檢測試劑盒和試劑
  • 市場分析、洞察與預測：按方法論分類
    • 免疫組織化學（IHC）
    • 免疫檢測
    • 分子診斷
      • 次世代定序（NGS）
      • 聚合酵素鏈鎖反應（PCR）
      • 原位雜合反應（ISH）
      • 其他
    • 其他
  • 市場分析、洞察與預測：按類型
    • 組織切片檢查
    • 液態生物檢體
  • 市場分析、洞察與預測：按癌症類型分類
    • 肺癌
    • 乳癌
    • 結腸癌
    • 攝護腺癌
    • 其他
  • 市場分析、洞察與預測：按最終用戶分類
    • 醫院和診所
    • 臨床檢查室
    • 其他
  • 市場分析、洞察與預測：按地區分類
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第6章：北美癌症診斷市場分析、洞察與預測（2021-2034年）

  • 國家
    • 美國
    • 加拿大

第7章：歐洲癌症診斷市場分析、洞察與預測（2021-2034年）

  • 國家
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 斯堪地那維亞
    • 其他歐洲國家

第8章：亞太地區癌症診斷市場分析、洞察與預測（2021-2034年）

  • 國家
    • 日本
    • 中國
    • 澳洲
    • 印度
    • 東南亞
    • 其他亞太國家

第9章：拉丁美洲癌症診斷市場分析、洞察與預測（2021-2034年）

  • 國家
    • 巴西
    • 墨西哥
    • 其他拉丁美洲國家

第10章：中東和非洲癌症診斷市場分析、洞察與預測（2021-2034年）

  • 國家
    • 南非
    • GCC
    • 其他中東和非洲國家

第11章 競爭分析

  • 全球市佔率分析（2025 年）
  • 市場主要企業概覽
    • F. Hoffmann-La Roche Ltd
    • Thermo Fisher Scientific Inc.
    • Abbott
    • Illumina, Inc.
    • GE Healthcare
    • BD
    • bioMerieux SA
    • Myriad Genetics, Inc
    • Bio-Rad Laboratories, Inc.
    • QIAGEN
Product Code: FBI110706

Growth Factors of cancer diagnostics Market

The global cancer diagnostics market is witnessing robust growth due to the rising burden of cancer, technological advancements in diagnostics, and increasing government initiatives promoting early detection. According to recent data, the market size was valued at USD 17.24 billion in 2025, and it is projected to reach USD 18.51 billion in 2026. By 2034, the market is expected to expand significantly to USD 38.27 billion, exhibiting a CAGR of 9.5% from 2026 to 2034.

Market Drivers

The increasing prevalence of cancers such as breast, colorectal, and prostate cancer is a primary driver fueling the demand for effective diagnostics. For instance, as per the World Health Organization (WHO), global new cancer cases are projected to reach 35 million by 2050, a 77% increase from 20 million in 2022. Early and precise diagnosis plays a critical role in reducing mortality rates, which has accelerated the adoption of advanced diagnostic solutions, including immunohistochemistry (IHC), in-situ hybridization (ISH), molecular diagnostics, and liquid biopsies.

Government and private organizations have increased initiatives to raise awareness regarding early cancer detection. Programs such as Against Colorectal Cancer in Our Neighborhoods (ACCION) in the U.S., Bowel Cancer Screening Programme (BCSP) in the U.K., and WHO's Global Strategy for Cervical Cancer Elimination aim to expand screening and early intervention efforts. These initiatives are boosting market growth by promoting diagnostic adoption.

Market Restraints

Despite growth, high costs and certain risks associated with diagnostic procedures remain challenges. For example, colonoscopy, a gold standard for colorectal cancer screening, carries risks like bleeding, perforation, and device-associated infections. Additionally, advanced diagnostic instruments such as PCR machines can range from USD 3,000 to USD 30,000, with ongoing maintenance costs, which limits adoption, especially in emerging markets.

Market Opportunities

Emerging markets in Asia Pacific are presenting lucrative opportunities for growth due to increasing government investment in healthcare infrastructure and rising awareness about telemedicine. The COVID-19 pandemic accelerated telemedicine adoption, enabling cancer screening and consultations remotely. This trend is expected to continue, providing access to underserved populations for early diagnosis and follow-ups.

Market Trends

Market players are increasingly focusing on product launches, technological advancements, and partnerships. Notable developments include:

  • June 2022: F. Hoffmann-La Roche Ltd launched BenchMark ULTRA PLUS to enhance timely cancer diagnosis.
  • October 2023: Partnership between F. Hoffmann-La Roche Ltd, Ibex Medical Analytics, and Amazon Web Services to expand AI-powered diagnostic tools for prostate and blood cancers.
  • April 2024: Novelna, a U.S.-based biotech company, developed a blood protein test capable of detecting 18 early-stage cancers with high accuracy.
  • May 2023: Pfizer Inc. and Thermo Fisher Scientific Inc. collaborated to enhance accessibility to NGS-based cancer diagnostics in over 30 countries.
  • April 2024: Bio-Rad Laboratories, Inc. launched the ddPLEX ESR1 Mutation Detection Kit for biomarker-based diagnostics.

Segmentation Analysis

By Product:

  • Assay kits & reagents dominate with 83.07% market share in 2026 due to the increasing number of diagnostic tests and new product launches.
  • Instruments are projected to grow steadily, driven by rising healthcare expenditures.

By Technique:

  • Immunoassays lead the market due to their efficacy in diagnosing breast, prostate, and other cancers.
  • IHC is anticipated to grow fastest, supported by precise diagnosis and treatment prediction capabilities.

By Type:

  • Tissue biopsy dominates with 87.04% market share in 2026, attributed to high accuracy and detailed molecular profiling.
  • Liquid biopsy is growing fastest due to faster result output, often 26.8 days quicker than tissue biopsies.

By Cancer Type:

  • Breast cancer segment remains dominant, reflecting the high global burden.
  • Lung cancer is growing rapidly due to increasing smoking prevalence among youth.

By End-user:

  • Clinical laboratories dominate the market due to high testing volumes and technologically advanced equipment.
  • Hospitals & clinics are also expanding, offering both diagnosis and treatment at the same location.

Regional Outlook

  • North America dominated in 2025 with 36.81% market share (USD 6.35 billion), projected to reach USD 6.9 billion in 2026, driven by companies like Thermo Fisher Scientific, Abbott, Illumina, and GE Healthcare.
  • Europe contributed USD 5.28 billion in 2025, reaching USD 5.63 billion in 2026, supported by partnerships and genome projects like the 100,000 Genomes Project.
  • Asia Pacific grew to USD 3.78 billion in 2025, projected at USD 4.07 billion in 2026, with rising cancer burden in countries like China, Japan, and India.
  • Latin America and Middle East & Africa are smaller but growing markets, valued at USD 1.13 billion and USD 0.69 billion in 2025, respectively.

Competitive Landscape

Key players like F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Abbott, Illumina, Inc., GE Healthcare, BD, bioMerieux SA, Myriad Genetics, Inc., Bio-Rad Laboratories, Inc., and QIAGEN dominate the market. Strategic partnerships, product launches, and technological innovations drive growth and expand market access.

Conclusion

The global cancer diagnostics market is poised for strong growth, reaching USD 38.27 billion by 2034. Increasing cancer prevalence, early detection initiatives, technological advancements, and regional expansion in emerging markets are key growth drivers. Despite challenges such as high costs and limited access in some regions, the market continues to evolve with AI integration, biomarker development, and personalized medicine, offering opportunities for improved patient outcomes worldwide.

Segmentation By Product

  • Instruments
  • Assay Kits & Reagents

By Technique

  • Immunohistochemistry (IHC)
  • Immunoassays
  • Molecular Diagnostics
    • Next Generation Sequencing (NGS)
    • Polymerase Chain Reaction (PCR)
    • In-situ Hybridization (ISH)
    • Others
  • Others

By Type

  • Tissue Biopsy
  • Liquid Biopsy

By Cancer Type

  • Lung Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Others

By End-user

  • Hospitals & Clinics
  • Clinical Laboratories
  • Others

By Region

  • North America (by Product, by Techniques, by Type, by Cancer Type, by End-user, and by Country)
    • U.S.
    • Canada
  • Europe (by Product, by Techniques, by Type, by Cancer Type, by End-user, and by Country/Sub-region)
    • U.K.
    • Germany
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (by Product, by Techniques, by Type, by Cancer Type, by End-user, and by Country/Sub-region)
    • Japan
    • China
    • Australia
    • India
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (by Product, by Techniques, by Type, by Cancer Type, by End-user, and by Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (by Product, by Techniques, by Type, by Cancer Type, by End-user, and by Country/Sub-region)
    • South Africa
    • GCC
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities

4. Key Insights

  • 4.1. Prevalence of Key Cancer, by Countries/Region in 2025
  • 4.2. New Product Launches by Key Players
  • 4.3. Recent Industry Developments - Mergers & Acquisitions
  • 4.4. Overview of Healthcare Expenditure by Key Countries
  • 4.5. Technological Advancements, Diagnostic Instruments & Kits
  • 4.6. Impact of COVID-19 on the Cancer Diagnostics Market

5. Global Cancer Diagnostics Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Product
    • 5.1.1. Instruments
    • 5.1.2. Assay Kits & Reagents
  • 5.2. Market Analysis, Insights and Forecast - By Technique
    • 5.2.1. Immunohistochemistry (IHC)
    • 5.2.2. Immunoassays
    • 5.2.3. Molecular Diagnostics
      • 5.2.3.1. Next Generation Sequencing (NGS)
      • 5.2.3.2. Polymerase Chain Reaction (PCR)
      • 5.2.3.3. In-situ Hybridization (ISH)
      • 5.2.3.4. Others
    • 5.2.4. Others
  • 5.3. Market Analysis, Insights and Forecast - By Type
    • 5.3.1. Tissue Biopsy
    • 5.3.2. Liquid Biopsy
  • 5.4. Market Analysis, Insights and Forecast - By Cancer Type
    • 5.4.1. Lung Cancer
    • 5.4.2. Breast Cancer
    • 5.4.3. Colorectal Cancer
    • 5.4.4. Prostate Cancer
    • 5.4.5. Others
  • 5.5. Market Analysis, Insights and Forecast - By End User
    • 5.5.1. Hospitals & Clinics
    • 5.5.2. Clinical Laboratories
    • 5.5.3. Others
  • 5.6. Market Analysis, Insights and Forecast - By Geography
    • 5.6.1. North America
    • 5.6.2. Europe
    • 5.6.3. Asia Pacific
    • 5.6.4. Latin America
    • 5.6.5. Middle East & Africa

6. North America Cancer Diagnostics Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Product
    • 6.1.1. Instruments
    • 6.1.2. Assay Kits & Reagents
  • 6.2. Market Analysis, Insights and Forecast - By Technique
    • 6.2.1. Immunohistochemistry (IHC)
    • 6.2.2. Immunoassays
    • 6.2.3. Molecular Diagnostics
      • 6.2.3.1. Next Generation Sequencing (NGS)
      • 6.2.3.2. Polymerase Chain Reaction (PCR)
      • 6.2.3.3. In-situ Hybridization (ISH)
      • 6.2.3.4. Others
    • 6.2.4. Others
  • 6.3. Market Analysis, Insights and Forecast - By Type
    • 6.3.1. Tissue Biopsy
    • 6.3.2. Liquid Biopsy
  • 6.4. Market Analysis, Insights and Forecast - By Cancer Type
    • 6.4.1. Lung Cancer
    • 6.4.2. Breast Cancer
    • 6.4.3. Colorectal Cancer
    • 6.4.4. Prostate Cancer
    • 6.4.5. Others
  • 6.5. Market Analysis, Insights and Forecast - By End User
    • 6.5.1. Hospitals & Clinics
    • 6.5.2. Clinical Laboratories
    • 6.5.3. Others
  • 6.6. Market Analysis, Insights and Forecast - By Country
    • 6.6.1. U.S.
    • 6.6.2. Canada

7. Europe Cancer Diagnostics Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Product
    • 7.1.1. Instruments
    • 7.1.2. Assay Kits & Reagents
  • 7.2. Market Analysis, Insights and Forecast - By Technique
    • 7.2.1. Immunohistochemistry (IHC)
    • 7.2.2. Immunoassays
    • 7.2.3. Molecular Diagnostics
      • 7.2.3.1. Next Generation Sequencing (NGS)
      • 7.2.3.2. Polymerase Chain Reaction (PCR)
      • 7.2.3.3. In-situ Hybridization (ISH)
      • 7.2.3.4. Others
    • 7.2.4. Others
  • 7.3. Market Analysis, Insights and Forecast - By Type
    • 7.3.1. Tissue Biopsy
    • 7.3.2. Liquid Biopsy
  • 7.4. Market Analysis, Insights and Forecast - By Cancer Type
    • 7.4.1. Lung Cancer
    • 7.4.2. Breast Cancer
    • 7.4.3. Colorectal Cancer
    • 7.4.4. Prostate Cancer
    • 7.4.5. Others
  • 7.5. Market Analysis, Insights and Forecast - By End User
    • 7.5.1. Hospitals & Clinics
    • 7.5.2. Clinical Laboratories
    • 7.5.3. Others
  • 7.6. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 7.6.1. U.K.
    • 7.6.2. Germany
    • 7.6.3. France
    • 7.6.4. Spain
    • 7.6.5. Italy
    • 7.6.6. Scandinavia
    • 7.6.7. Rest of Europe

8. Asia Pacific Cancer Diagnostics Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Product
    • 8.1.1. Instruments
    • 8.1.2. Assay Kits & Reagents
  • 8.2. Market Analysis, Insights and Forecast - By Technique
    • 8.2.1. Immunohistochemistry (IHC)
    • 8.2.2. Immunoassays
    • 8.2.3. Molecular Diagnostics
      • 8.2.3.1. Next Generation Sequencing (NGS)
      • 8.2.3.2. Polymerase Chain Reaction (PCR)
      • 8.2.3.3. In-situ Hybridization (ISH)
      • 8.2.3.4. Others
    • 8.2.4. Others
  • 8.3. Market Analysis, Insights and Forecast - By Type
    • 8.3.1. Tissue Biopsy
    • 8.3.2. Liquid Biopsy
  • 8.4. Market Analysis, Insights and Forecast - By Cancer Type
    • 8.4.1. Lung Cancer
    • 8.4.2. Breast Cancer
    • 8.4.3. Colorectal Cancer
    • 8.4.4. Prostate Cancer
    • 8.4.5. Others
  • 8.5. Market Analysis, Insights and Forecast - By End User
    • 8.5.1. Hospitals & Clinics
    • 8.5.2. Clinical Laboratories
    • 8.5.3. Others
  • 8.6. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 8.6.1. Japan
    • 8.6.2. China
    • 8.6.3. Australia
    • 8.6.4. India
    • 8.6.5. Southeast Asia
    • 8.6.6. Rest of Asia Pacific

9. Latin America Cancer Diagnostics Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Product
    • 9.1.1. Instruments
    • 9.1.2. Assay Kits & Reagents
  • 9.2. Market Analysis, Insights and Forecast - By Technique
    • 9.2.1. Immunohistochemistry (IHC)
    • 9.2.2. Immunoassays
    • 9.2.3. Molecular Diagnostics
      • 9.2.3.1. Next Generation Sequencing (NGS)
      • 9.2.3.2. Polymerase Chain Reaction (PCR)
      • 9.2.3.3. In-situ Hybridization (ISH)
      • 9.2.3.4. Others
    • 9.2.4. Others
  • 9.3. Market Analysis, Insights and Forecast - By Type
    • 9.3.1. Tissue Biopsy
    • 9.3.2. Liquid Biopsy
  • 9.4. Market Analysis, Insights and Forecast - By Cancer Type
    • 9.4.1. Lung Cancer
    • 9.4.2. Breast Cancer
    • 9.4.3. Colorectal Cancer
    • 9.4.4. Prostate Cancer
    • 9.4.5. Others
  • 9.5. Market Analysis, Insights and Forecast - By End User
    • 9.5.1. Hospitals & Clinics
    • 9.5.2. Clinical Laboratories
    • 9.5.3. Others
  • 9.6. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 9.6.1. Brazil
    • 9.6.2. Mexico
    • 9.6.3. Rest of Latin America

10. Middle East & Africa Cancer Diagnostics Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Product
    • 10.1.1. Instruments
    • 10.1.2. Assay Kits & Reagents
  • 10.2. Market Analysis, Insights and Forecast - By Technique
    • 10.2.1. Immunohistochemistry (IHC)
    • 10.2.2. Immunoassays
    • 10.2.3. Molecular Diagnostics
      • 10.2.3.1. Next Generation Sequencing (NGS)
      • 10.2.3.2. Polymerase Chain Reaction (PCR)
      • 10.2.3.3. In-situ Hybridization (ISH)
      • 10.2.3.4. Others
    • 10.2.4. Others
  • 10.3. Market Analysis, Insights and Forecast - By Type
    • 10.3.1. Tissue Biopsy
    • 10.3.2. Liquid Biopsy
  • 10.4. Market Analysis, Insights and Forecast - By Cancer Type
    • 10.4.1. Lung Cancer
    • 10.4.2. Breast Cancer
    • 10.4.3. Colorectal Cancer
    • 10.4.4. Prostate Cancer
    • 10.4.5. Others
  • 10.5. Market Analysis, Insights and Forecast - By End User
    • 10.5.1. Hospitals & Clinics
    • 10.5.2. Clinical Laboratories
    • 10.5.3. Others
  • 10.6. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 10.6.1. South Africa
    • 10.6.2. GCC
    • 10.6.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Profiles of Players Operating in the Market
    • 11.2.1. F. Hoffmann-La Roche Ltd
      • 11.2.1.1. Overview
      • 11.2.1.2. Products & services
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. Financials (Based on Availability)
    • 11.2.2. Thermo Fisher Scientific Inc.
      • 11.2.2.1. Overview
      • 11.2.2.2. Products & services
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. Financials (Based on Availability)
    • 11.2.3. Abbott
      • 11.2.3.1. Overview
      • 11.2.3.2. Products & services
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. Financials (Based on Availability)
    • 11.2.4. Illumina, Inc.
      • 11.2.4.1. Overview
      • 11.2.4.2. Products & services
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. Financials (Based on Availability)
    • 11.2.5. GE Healthcare
      • 11.2.5.1. Overview
      • 11.2.5.2. Products & services
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. Financials (Based on Availability)
    • 11.2.6. BD
      • 11.2.6.1. Overview
      • 11.2.6.2. Products & services
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. Financials (Based on Availability)
    • 11.2.7. bioMerieux SA
      • 11.2.7.1. Overview
      • 11.2.7.2. Products & services
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. Financials (Based on Availability)
    • 11.2.8. Myriad Genetics, Inc
      • 11.2.8.1. Overview
      • 11.2.8.2. Products & services
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. Financials (Based on Availability)
    • 11.2.9. Bio-Rad Laboratories, Inc.
      • 11.2.9.1. Overview
      • 11.2.9.2. Products & services
      • 11.2.9.3. SWOT Analysis
      • 11.2.9.4. Recent Developments
      • 11.2.9.5. Strategies
      • 11.2.9.6. Financials (Based on Availability)
    • 11.2.10. QIAGEN
      • 11.2.10.1. Overview
      • 11.2.10.2. Products & services
      • 11.2.10.3. SWOT Analysis
      • 11.2.10.4. Recent Developments
      • 11.2.10.5. Strategies
      • 11.2.10.6. Financials (Based on Availability)

List of Tables

  • Table 1: Global Cancer Diagnostics Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 2: Global Cancer Diagnostics Market Revenue (USD billion) Forecast, by Technique, 2021-2034
  • Table 3: Global Cancer Diagnostics Market Revenue (USD billion) Forecast, by Molecular Diagnostics, 2021-2034
  • Table 4: Global Cancer Diagnostics Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 5: Global Cancer Diagnostics Market Revenue (USD billion) Forecast, by Cancer Type, 2021-2034
  • Table 6: Global Cancer Diagnostics Market Revenue (USD billion) Forecast, by End-user, 2021-2034
  • Table 7: Global Cancer Diagnostics Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 8: North America Cancer Diagnostics Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 9: North America Cancer Diagnostics Market Revenue (USD billion) Forecast, by Technique, 2021-2034
  • Table 10: North America Cancer Diagnostics Market Revenue (USD billion) Forecast, by Molecular Diagnostics, 2021-2034
  • Table 11: North America Cancer Diagnostics Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 12: North America Cancer Diagnostics Market Revenue (USD billion) Forecast, by Cancer Type, 2021-2034
  • Table 13: North America Cancer Diagnostics Market Revenue (USD billion) Forecast, by End-user, 2021-2034
  • Table 14: North America Cancer Diagnostics Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 15: Europe Cancer Diagnostics Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 16: Europe Cancer Diagnostics Market Revenue (USD billion) Forecast, by Technique, 2021-2034
  • Table 17: Europe Cancer Diagnostics Market Revenue (USD billion) Forecast, by Molecular Diagnostics, 2021-2034
  • Table 18: Europe Cancer Diagnostics Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 19: Europe Cancer Diagnostics Market Revenue (USD billion) Forecast, by Cancer Type, 2021-2034
  • Table 20: Europe Cancer Diagnostics Market Revenue (USD billion) Forecast, by End-user, 2021-2034
  • Table 21: Europe Cancer Diagnostics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 22: Asia Pacific Cancer Diagnostics Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 23: Asia Pacific Cancer Diagnostics Market Revenue (USD billion) Forecast, by Technique, 2021-2034
  • Table 24: Asia Pacific Cancer Diagnostics Market Revenue (USD billion) Forecast, by Molecular Diagnostics, 2021-2034
  • Table 25: Asia Pacific Cancer Diagnostics Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 26: Asia Pacific Cancer Diagnostics Market Revenue (USD billion) Forecast, by Cancer Type, 2021-2034
  • Table 27: Asia Pacific Cancer Diagnostics Market Revenue (USD billion) Forecast, by End-user, 2021-2034
  • Table 28: Asia Pacific Cancer Diagnostics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 29: Latin America Cancer Diagnostics Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 30: Latin America Cancer Diagnostics Market Revenue (USD billion) Forecast, by Technique, 2021-2034
  • Table 31: Latin America Cancer Diagnostics Market Revenue (USD billion) Forecast, by Molecular Diagnostics, 2021-2034
  • Table 32: Latin America Cancer Diagnostics Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 33: Latin America Cancer Diagnostics Market Revenue (USD billion) Forecast, by Cancer Type, 2021-2034
  • Table 34: Latin America Cancer Diagnostics Market Revenue (USD billion) Forecast, by End-user, 2021-2034
  • Table 35: Latin America Cancer Diagnostics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 36: Middle East & Africa Cancer Diagnostics Market Revenue (USD billion) Forecast, by Product, 2021-2034
  • Table 37: Middle East & Africa Cancer Diagnostics Market Revenue (USD billion) Forecast, by Technique, 2021-2034
  • Table 38: Middle East & Africa Cancer Diagnostics Market Revenue (USD billion) Forecast, by Molecular Diagnostics, 2021-2034
  • Table 39: Middle East & Africa Cancer Diagnostics Market Revenue (USD billion) Forecast, by Type, 2021-2034
  • Table 40: Middle East & Africa Cancer Diagnostics Market Revenue (USD billion) Forecast, by Cancer Type, 2021-2034
  • Table 41: Middle East & Africa Cancer Diagnostics Market Revenue (USD billion) Forecast, by End-user, 2021-2034
  • Table 42: Middle East & Africa Cancer Diagnostics Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Cancer Diagnostics Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Cancer Diagnostics Market Value Share (%), by Product, 2025 & 2034
  • Figure 3: Global Cancer Diagnostics Market Value Share (%), by Technique, 2025 & 2034
  • Figure 4: Global Cancer Diagnostics Market Value Share (%), by Type, 2025 & 2034
  • Figure 5: Global Cancer Diagnostics Market Value Share (%), by Cancer Type, 2025 & 2034
  • Figure 6: Global Cancer Diagnostics Market Value Share (%), by End-user, 2025 & 2034
  • Figure 7: Global Cancer Diagnostics Market Value (USD billion), by Region, 2025 & 2034
  • Figure 8: North America Cancer Diagnostics Market Value (USD billion), by Product, 2025 & 2034
  • Figure 9: North America Cancer Diagnostics Market Value Share (%), by Product, 2025
  • Figure 10: North America Cancer Diagnostics Market Value (USD billion), by Technique, 2025 & 2034
  • Figure 11: North America Cancer Diagnostics Market Value Share (%), by Technique, 2025
  • Figure 12: North America Cancer Diagnostics Market Value (USD billion), by Type, 2025 & 2034
  • Figure 13: North America Cancer Diagnostics Market Value Share (%), by Type, 2025
  • Figure 14: North America Cancer Diagnostics Market Value (USD billion), by Cancer Type, 2025 & 2034
  • Figure 15: North America Cancer Diagnostics Market Value Share (%), by Cancer Type, 2025
  • Figure 16: North America Cancer Diagnostics Market Value (USD billion), by End-user, 2025 & 2034
  • Figure 17: North America Cancer Diagnostics Market Value Share (%), by End-user, 2025
  • Figure 18: North America Cancer Diagnostics Market Value (USD billion), By Country, 2025 & 2034
  • Figure 19: North America Cancer Diagnostics Market Value Share (%), By Country, 2025
  • Figure 20: Europe Cancer Diagnostics Market Value (USD billion), by Product, 2025 & 2034
  • Figure 21: Europe Cancer Diagnostics Market Value Share (%), by Product, 2025
  • Figure 22: Europe Cancer Diagnostics Market Value (USD billion), by Technique, 2025 & 2034
  • Figure 23: Europe Cancer Diagnostics Market Value Share (%), by Technique, 2025
  • Figure 24: Europe Cancer Diagnostics Market Value (USD billion), by Type, 2025 & 2034
  • Figure 25: Europe Cancer Diagnostics Market Value Share (%), by Type, 2025
  • Figure 26: Europe Cancer Diagnostics Market Value (USD billion), by Cancer Type, 2025 & 2034
  • Figure 27: Europe Cancer Diagnostics Market Value Share (%), by Cancer Type, 2025
  • Figure 28: Europe Cancer Diagnostics Market Value (USD billion), by End-user, 2025 & 2034
  • Figure 29: Europe Cancer Diagnostics Market Value Share (%), by End-user, 2025
  • Figure 30: Europe Cancer Diagnostics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 31: Europe Cancer Diagnostics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 32: Asia Pacific Cancer Diagnostics Market Value (USD billion), by Product, 2025 & 2034
  • Figure 33: Asia Pacific Cancer Diagnostics Market Value Share (%), by Product, 2025
  • Figure 34: Asia Pacific Cancer Diagnostics Market Value (USD billion), by Technique, 2025 & 2034
  • Figure 35: Asia Pacific Cancer Diagnostics Market Value Share (%), by Technique, 2025
  • Figure 36: Asia Pacific Cancer Diagnostics Market Value (USD billion), by Type, 2025 & 2034
  • Figure 37: Asia Pacific Cancer Diagnostics Market Value Share (%), by Type, 2025
  • Figure 38: Asia Pacific Cancer Diagnostics Market Value (USD billion), by Cancer Type, 2025 & 2034
  • Figure 39: Asia Pacific Cancer Diagnostics Market Value Share (%), by Cancer Type, 2025
  • Figure 40: Asia Pacific Cancer Diagnostics Market Value (USD billion), by End-user, 2025 & 2034
  • Figure 41: Asia Pacific Cancer Diagnostics Market Value Share (%), by End-user, 2025
  • Figure 42: Asia Pacific Cancer Diagnostics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 43: Asia Pacific Cancer Diagnostics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 44: Latin America Cancer Diagnostics Market Value (USD billion), by Product, 2025 & 2034
  • Figure 45: Latin America Cancer Diagnostics Market Value Share (%), by Product, 2025
  • Figure 46: Latin America Cancer Diagnostics Market Value (USD billion), by Technique, 2025 & 2034
  • Figure 47: Latin America Cancer Diagnostics Market Value Share (%), by Technique, 2025
  • Figure 48: Latin America Cancer Diagnostics Market Value (USD billion), by Type, 2025 & 2034
  • Figure 49: Latin America Cancer Diagnostics Market Value Share (%), by Type, 2025
  • Figure 50: Latin America Cancer Diagnostics Market Value (USD billion), by Cancer Type, 2025 & 2034
  • Figure 51: Latin America Cancer Diagnostics Market Value Share (%), by Cancer Type, 2025
  • Figure 52: Latin America Cancer Diagnostics Market Value (USD billion), by End-user, 2025 & 2034
  • Figure 53: Latin America Cancer Diagnostics Market Value Share (%), by End-user, 2025
  • Figure 54: Latin America Cancer Diagnostics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 55: Latin America Cancer Diagnostics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 56: Middle East & Africa Cancer Diagnostics Market Value (USD billion), by Product, 2025 & 2034
  • Figure 57: Middle East & Africa Cancer Diagnostics Market Value Share (%), by Product, 2025
  • Figure 58: Middle East & Africa Cancer Diagnostics Market Value (USD billion), by Technique, 2025 & 2034
  • Figure 59: Middle East & Africa Cancer Diagnostics Market Value Share (%), by Technique, 2025
  • Figure 60: Middle East & Africa Cancer Diagnostics Market Value (USD billion), by Type, 2025 & 2034
  • Figure 61: Middle East & Africa Cancer Diagnostics Market Value Share (%), by Type, 2025
  • Figure 62: Middle East & Africa Cancer Diagnostics Market Value (USD billion), by Cancer Type, 2025 & 2034
  • Figure 63: Middle East & Africa Cancer Diagnostics Market Value Share (%), by Cancer Type, 2025
  • Figure 64: Middle East & Africa Cancer Diagnostics Market Value (USD billion), by End-user, 2025 & 2034
  • Figure 65: Middle East & Africa Cancer Diagnostics Market Value Share (%), by End-user, 2025
  • Figure 66: Middle East & Africa Cancer Diagnostics Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 67: Middle East & Africa Cancer Diagnostics Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 68: Global Cancer Diagnostics Market Share (%), By Company, 2025